Lab
Quest Diagnostics Clinical Laboratories INC
Quest Diagnostics Clinical Laboratories INC was paid $14.27M by Medicaid between Mar 2018 and Dec 2024, across 104 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 24% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
DENVER, CO 80209
DENVER, CO 80209
33aNPI1013431741assigned 08/03/2017
33bProvider typeClinical Medical Laboratory
28Total paid$14.27M
24GClaims1,118,025
24DCodes billed104
24AFirst – last monthMar 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Colorado
Rank by total paid#5 of 91
Median peer was paid$53K
This provider vs. median268×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,325 | $1.13M | |
| 2019 | 141,500 | $1.52M | |
| 2020 | 138,745 | $2.23M | |
| 2021 | 207,529 | $3.76M | |
| 2022 | 170,812 | $2.13M | |
| 2023 | 196,787 | $1.86M | |
| 2024incomplete | 156,327 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 24% | 47,583 | 44,542 | $3.46M |
| 80050 | General health panel | 8.7% | 30,889 | 30,041 | $1.24M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 8.1% | 147,918 | 137,118 | $1.15M |
| 87088 | 6.4% | 112,142 | 104,127 | $915K | |
| 80053 | Comprehensive metabolic panel | 5.6% | 79,017 | 70,162 | $797K |
| 80061 | Lipid panel | 5.1% | 55,779 | 54,200 | $727K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.6% | 28,365 | 26,975 | $655K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.4% | 51,889 | 50,429 | $483K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.2% | 28,787 | 27,644 | $463K |
| 87186 | 2.5% | 41,629 | 38,885 | $350K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 48,987 | 43,526 | $345K |
| 87081 | 2.3% | 47,508 | 45,581 | $323K |
92 more codes
| 87077 | 2.1% | 39,882 | $301K | |
| 87070 | 2.0% | 33,494 | $282K | |
| 82728 | 1.5% | 16,295 | $214K | |
| 82607 | 1.1% | 10,636 | $156K | |
| 84439 | <1% | 15,526 | $134K | |
| 87147 | <1% | 19,542 | $111K | |
| 83550 | <1% | 13,174 | $108K | |
| 87209 | <1% | 5,453 | $96K | |
| 83013 | <1% | 1,487 | $96K | |
| 82274 | <1% | 7,288 | $95K | |
| 82746 | <1% | 6,577 | $94K | |
| 83540 | <1% | 14,156 | $88K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,969 | $83K |
| 84153 | <1% | 4,755 | $83K | |
| 82670 | <1% | 2,749 | $74K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,670 | $70K |
| 84702 | <1% | 4,399 | $64K | |
| 87338 | <1% | 4,686 | $64K | |
| 83001 | <1% | 3,381 | $62K | |
| 85027 | <1% | 10,311 | $60K | |
| 87177 | <1% | 5,436 | $54K | |
| 86140 | <1% | 10,702 | $52K | |
| 82247 | <1% | 10,720 | $48K | |
| 87427 | <1% | 3,883 | $46K | |
| 84146 | <1% | 2,161 | $41K | |
| 83735 | <1% | 6,648 | $41K | |
| 83002 | <1% | 2,237 | $41K | |
| 87045 | <1% | 4,202 | $39K | |
| 83880 | <1% | 1,080 | $39K | |
| 82248 | <1% | 8,238 | $38K | |
| 87329 | <1% | 3,091 | $37K | |
| 81001 | <1% | 12,125 | $36K | |
| 87075 | <1% | 4,268 | $35K | |
| 81003 | <1% | 16,196 | $34K | |
| 87449 | <1% | 2,927 | $29K | |
| 84144 | <1% | 1,495 | $29K | |
| 87205 | <1% | 5,339 | $23K | |
| 83615 | <1% | 3,584 | $21K | |
| 84550 | <1% | 4,531 | $19K | |
| 83690 | <1% | 2,863 | $19K | |
| 85652 | <1% | 7,206 | $19K | |
| 82950 | <1% | 3,945 | $19K | |
| 87324 | <1% | 1,572 | $18K | |
| 84460 | <1% | 3,419 | $18K | |
| 82570 | <1% | 3,254 | $17K | |
| 80076 | <1% | 2,043 | $17K | |
| 84100 | <1% | 3,814 | $16K | |
| 82550 | <1% | 2,166 | $13K | |
| 87046 | <1% | 2,483 | $13K | |
| 85610 | <1% | 3,266 | $13K | |
| 84450 | <1% | 2,464 | $13K | |
| 84156 | <1% | 3,346 | $12K | |
| 83721 | <1% | 961 | $9K | |
| 80164 | <1% | 826 | $9K | |
| 81015 | <1% | 2,739 | $8K | |
| 84436 | <1% | 1,452 | $8K | |
| 84478 | <1% | 1,558 | $8K | |
| 82150 | <1% | 1,016 | $6K | |
| 87076 | <1% | 734 | $6K | |
| 82977 | <1% | 861 | $6K | |
| 80178 | <1% | 794 | $5K | |
| 85730 | <1% | 791 | $5K | |
| 85004 | <1% | 626 | $4K | |
| 84703 | <1% | 535 | $4K | |
| 83014 | <1% | 445 | $3K | |
| 85045 | <1% | 793 | $3K | |
| 85018 | <1% | 1,088 | $3K | |
| 82947 | <1% | 599 | $3K | |
| 85379 | <1% | 268 | $2K | |
| 82565 | <1% | 434 | $2K | |
| 85014 | <1% | 841 | $2K | |
| 89055 | <1% | 370 | $2K | |
| 85048 | <1% | 668 | $2K | |
| 80069 | <1% | 146 | $1K | |
| 89060 | <1% | 13 | $763.58 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 53 | $716.76 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 25 | $687.60 |
| 82951 | <1% | 60 | $656.37 | |
| 82465 | <1% | 158 | $644.55 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,936 | $570.48 |
| 84479 | <1% | 85 | $437.58 | |
| 82140 | <1% | 15 | $230.88 | |
| 85041 | <1% | 69 | $199.98 | |
| 82952 | <1% | 57 | $192.08 | |
| 82040 | <1% | 35 | $158.40 | |
| 85007 | <1% | 44 | $155.80 | |
| 83718 | <1% | 18 | $147.42 | |
| 86308 | <1% | 28 | $103.60 | |
| 87185 | <1% | 15 | $72.33 | |
| 36416 | 0% | 149 | $0.00 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 0% | 13 | $0.00 |
| 99001 | 0% | 80 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.